Zydus Lifesciences shares experienced a 4.8% increase, reaching an intra-day high of ₹984.9 on the Bombay Stock Exchange (BSE), as investors reacted to the announcement of a board meeting scheduled for May 19, 2026. During this meeting, the board will consider a proposal for the buyback of fully paid-up equity shares in accordance with the Companies Act, 2013, and related regulations. Additionally, Zydus Lifesciences has signed an agreement to acquire Assertio Holdings, a US-based specialty pharmaceutical company, for $23.50 per share, totaling approximately $166.4 million. This acquisition will be executed through Zydus Worldwide DMCC and will provide Zydus with immediate access to the US oncology market, leveraging Assertio's established network of over 170 community oncology accounts. The transaction is structured as a tender offer followed by a merger, pending regulatory approvals and customary closing conditions.